Intas Pharmaceuticals Ltd - Company Profile
Powered by 
All the data and insights you need on Intas Pharmaceuticals Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Intas Pharmaceuticals Ltd Strategy Report
- Understand Intas Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and commercializes pharmaceuticals and biotechnology products for the treatment of a wide range of diseases and disorders in various therapeutic segments. The company offers products such as sevelamer, ciprofloxacin, amitriptyline, erythropoietin, filgrastim, follicle-stimulating hormone (FSH), rituximab, ampicillin, albendazole, benazepril, and carprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma-derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma-derived product-based therapies. It has formulation manufacturing facilities and active pharmaceutical ingredients (API) and intermediate facilities in India. The company markets products through an internal sales force and a network of distributors worldwide. Intas is headquartered in Ahmedabad, Gujarat, India.
Headquarters
India
Address
Corporate House, S. G. Highway, Near Sola Bridge, Thaltej, Ahmedabad, Gujarat, 380054
Website
www.intaspharma.com
Telephone
91 79 61577000
Industry
Pharmaceuticals and Healthcare
Intas Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Therapy Areas: | Service: | Aspasweet |
| Cardiovascular | Contract Manufacturing | Selgin |
| Diabetology | Axepta | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In June, the company launched TOFATAS, Tofacitinib Ointment 2% w/w to treat patients with mild to moderate Atopic Dermatitis (AD) in patients 18 years and above. |
| 2022 | Contracts/Agreements | In April, the company entered into a research collaboration with Comera Life Sciences, Inc. to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. |
| 2021 | Contracts/Agreements | In September, the company and Arecor Therapeutics entered into a formulation agreement to use Arecor's proprietary formulation technology platform, Arestat. |
Competitor Comparison
| Key Parameters | Intas Pharmaceuticals Ltd | Lupin Ltd | Torrent Pharmaceuticals Ltd | Adline Chem Lab Ltd | Allied Chemicals and Pharmaceuticals Pvt Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Ahmedabad | Mumbai | Ahmedabad | Ahmedabad | New Delhi |
| State/Province | Gujarat | Maharashtra | Gujarat | Gujarat | Delhi |
| No. of Employees | - | 18,971 | 13,573 | 27 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Binish Hasmukh Chudgar | Vice Chairman; Managing Director | Executive Board | 2016 | - |
| Nimish Hasmukhbhai Chudgar | Managing Director; Director; Chief Executive Officer | Executive Board | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward